Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Clinical trials have shown greater weight loss with Tirzepatide, with some studies reaching up to 22.5% weight loss on average
Segn las guas actuales de la American Diabetes Association (ADA), estos medicamentos pueden considerarse como terapia inicial o adicional en pacientes con diabetes tipo 2, especialmente aquellos con enfermedad cardiovascular establecida, alto riesgo cardiovascular, enfermedad renal crnica o insuficiencia cardaca, independientemente del uso de metformina
Zepbound is $349-$499 depending on the dose
Lillys triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release
HIGHLY RECOMMEND
US$ 23.27
US$ 21.39
US$ 24.11
US$ 20.76
US$ 29.51
US$ 23.32
